$UG
UNITED GUARDIAN INC

2024 Q1 Form 10-K Financial Statement

#000117184324001526 Filed on March 22, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $3.255M $2.607M $10.89M
YoY Change 26.64% -5.64% -14.28%
Cost Of Revenue $1.556M $1.208M $5.480M
YoY Change 42.33% -20.37% -8.62%
Gross Profit $1.698M $1.399M $5.406M
YoY Change 15.01% 12.28% -19.35%
Gross Profit Margin 52.18% 53.68% 49.66%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $103.0K $110.2K $464.0K
YoY Change -18.89% -12.51% -5.46%
% of Gross Profit 6.06% 7.87% 8.58%
Depreciation & Amortization $23.71K $35.68K $105.7K
YoY Change -3.04% 9.62% -21.95%
% of Gross Profit 1.4% 2.55% 1.96%
Operating Expenses $103.0K $608.2K $464.0K
YoY Change -18.89% 1.25% -5.46%
Operating Profit $1.027M $791.3K $2.863M
YoY Change 23.42% 22.53% -29.08%
Interest Expense $139.6K $139.7K $387.8K
YoY Change 15.99% -29.65% -147.9%
% of Operating Profit 13.6% 17.65% 13.54%
Other Income/Expense, Net $139.6K $387.7K
YoY Change 15.99% -147.9%
Pretax Income $1.166M $930.9K $3.251M
YoY Change 22.48% 10.27% 0.72%
Income Tax $240.7K $193.5K $669.4K
% Of Pretax Income 20.64% 20.78% 20.59%
Net Earnings $925.4K $737.4K $2.581M
YoY Change 22.4% 8.57% 0.46%
Net Earnings / Revenue 28.43% 28.29% 23.71%
Basic Earnings Per Share $0.20 $0.56
Diluted Earnings Per Share $0.20 $0.16 $0.56
COMMON SHARES
Basic Shares Outstanding 4.594M 4.594M 4.594M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.610M $9.094M $9.094M
YoY Change 23.49% 40.26% 40.26%
Cash & Equivalents $7.073M $8.243M $8.243M
Short-Term Investments $1.536M $851.3K $851.3K
Other Short-Term Assets $408.5K $367.9K $367.9K
YoY Change 27.86% -4.94% -4.94%
Inventory $1.279M $1.224M $1.224M
Prepaid Expenses
Receivables $2.133M $1.567M $1.567M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.43M $12.25M $12.25M
YoY Change 10.57% 22.89% 22.89%
LONG-TERM ASSETS
Property, Plant & Equipment $617.4K $619.2K $619.2K
YoY Change 14.92% 10.74% 10.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $50.93K $50.93K
YoY Change -100.0% -53.93% -53.93%
Total Long-Term Assets $617.4K $670.1K $670.1K
YoY Change -11.59% 0.06% 0.06%
TOTAL ASSETS
Total Short-Term Assets $12.43M $12.25M $12.25M
Total Long-Term Assets $617.4K $670.1K $670.1K
Total Assets $13.05M $12.92M $12.92M
YoY Change 9.27% 21.45% 21.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $418.7K $134.4K $134.5K
YoY Change -5.18% 342.05% 341.98%
Accrued Expenses $1.422M $1.363M $1.363M
YoY Change 8.24% 3.1% 3.1%
Deferred Revenue $0.00 $15.50K
YoY Change -100.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.862M $1.534M $1.534M
YoY Change -2.88% 11.69% 11.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.862M $1.534M $1.534M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.882M $1.534M $1.534M
YoY Change -1.86% 11.69% 11.69%
SHAREHOLDERS EQUITY
Retained Earnings $10.71M $10.93M
YoY Change 11.95% 24.09%
Common Stock $459.4K $459.4K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.17M $11.39M $11.39M
YoY Change
Total Liabilities & Shareholders Equity $13.05M $12.92M $12.92M
YoY Change 9.27% 21.45% 21.45%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income $925.4K $737.4K $2.581M
YoY Change 22.4% 8.57% 0.46%
Depreciation, Depletion And Amortization $23.71K $35.68K $105.7K
YoY Change -3.04% 9.62% -21.95%
Cash From Operating Activities $644.1K $1.124M $3.144M
YoY Change 54.25% 80.0% 24.53%
INVESTING ACTIVITIES
Capital Expenditures $21.96K $95.72K $165.7K
YoY Change 750.35% 537.71% 120.43%
Acquisitions
YoY Change
Other Investing Activities -$643.5K $93.29K $4.893M
YoY Change 1379.02% -91.88% 403.04%
Cash From Investing Activities -$665.5K -$2.420K $4.728M
YoY Change 1343.93% -100.21% 426.71%
FINANCING ACTIVITIES
Cash Dividend Paid $1.148M $459.4K
YoY Change -85.29%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$1.148M 610.0 -$459.4K
YoY Change -100.04% -85.29%
NET CHANGE
Cash From Operating Activities $644.1K 1.124M $3.144M
Cash From Investing Activities -$665.5K -2.420K $4.728M
Cash From Financing Activities -$1.148M 610.0 -$459.4K
Net Change In Cash -$1.170M 1.123M $7.413M
YoY Change -414.89% 236.21% 2377.17%
FREE CASH FLOW
Cash From Operating Activities $644.1K $1.124M $3.144M
Capital Expenditures $21.96K $95.72K $165.7K
Free Cash Flow $622.2K $1.029M $2.979M
YoY Change 49.92% 68.73% 21.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000101295
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2022Q4 us-gaap Deferred Tax Liabilities Unrealized Gains On Trading Securities
DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
-0 usd
CY2023Q4 us-gaap Deferred Tax Assets Unrealized Losses On Availablefor Sale Securities Gross
DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross
0 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0 pure
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation Deductions Dividends
EffectiveIncomeTaxRateReconciliationDeductionsDividends
-0 pure
CY2023 us-gaap Income Tax Reconciliation Deductions Dividends
IncomeTaxReconciliationDeductionsDividends
-0 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0 pure
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 usd
CY2022Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
0 usd
CY2023 us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022 ug Number Of Vendors
NumberOfVendors
6 pure
CY2023 ug Number Of Vendors
NumberOfVendors
6 pure
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2023 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.1
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
37949075 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4594319
CY2023 dei Auditor Firm
AuditorFirmId
606
CY2023 dei Auditor Name
AuditorName
GRASSI & CO., CPAs, P.C.
CY2023 dei Auditor Location
AuditorLocation
Jericho, New York
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10885154 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12698503 usd
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5479566 usd
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5996376 usd
CY2023 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2078564 usd
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2174127 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
463992 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
490770 usd
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
8022122 usd
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
8661273 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
2863032 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
4037230 usd
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
236695 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3250778 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
669408 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
658168 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
2581370 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2569512 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4594319
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4594319
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8243122 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
830452 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
851318 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
5653516 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
16672 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
20063 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1566839 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1427576 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1223506 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1672012 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
191708 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
201846 usd
CY2023Q4 us-gaap Prepaid Taxes
PrepaidTaxes
176220 usd
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
185228 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
12252713 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9970630 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
50930 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
110544 usd
CY2023Q4 us-gaap Land
Land
69000 usd
CY2022Q4 us-gaap Land
Land
69000 usd
CY2023Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
4669936 usd
CY2022Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
4585055 usd
CY2023Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
2976577 usd
CY2022Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
2895742 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7715513 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7549797 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7096318 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6990636 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
619195 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
559161 usd
CY2023Q4 us-gaap Assets
Assets
12922838 usd
CY2022Q4 us-gaap Assets
Assets
10640335 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
134449 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
30415 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1363044 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1322056 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
15498 usd
CY2023Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
21265 usd
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
21220 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1534256 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1373691 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4594319
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4594319
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4594319
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4594319
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
459432 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
459432 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
10929150 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
8807212 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11388582 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9266644 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12922838 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10640335 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
9821269 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2569512 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9266644 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
2581370 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11388582 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
2581370 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2569512 usd
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
105682 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
135396 usd
CY2023 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
10000 usd
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2445 usd
CY2023 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
81095 usd
CY2022 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-1046245 usd
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-3391 usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-189 usd
CY2023 us-gaap Inventory Write Down
InventoryWriteDown
-17000 usd
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
29000 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
59614 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-193766 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
135872 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-385959 usd
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-465506 usd
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
290223 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10138 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9267 usd
CY2023 us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
-9008 usd
CY2022 us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
185228 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
104034 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-380479 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
40988 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-305334 usd
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
15498 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-190164 usd
CY2022 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-88738 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3144480 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2525169 usd
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
165716 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
75179 usd
CY2023 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
10000 usd
CY2022 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
37039 usd
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
621852 usd
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1931969 usd
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5505145 usd
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2867671 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4727577 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
897562 usd
CY2023 us-gaap Payments Of Dividends
PaymentsOfDividends
459387 usd
CY2022 us-gaap Payments Of Dividends
PaymentsOfDividends
3123492 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-459387 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3123492 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7412670 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
299239 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
830452 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
531213 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8243122 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
830452 usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
600000 usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1125000 usd
CY2023Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
45 usd
CY2022Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
645 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Use of Estimates</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for credit losses, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.</p>
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
16672 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
20063 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
15498 usd
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10885154 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12698503 usd
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10885154 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12698503 usd
CY2023Q3 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.1
CY2023 us-gaap Dividends
Dividends
459432 usd
CY2023 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
459387 usd
CY2023Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
45 usd
CY2022Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.37
CY2022Q4 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.31
CY2022 us-gaap Dividends
Dividends
3124137 usd
CY2022 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
3123492 usd
CY2022Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
645 usd
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Concentration of Credit Risk</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Accounts receivable potentially expose the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended December 31, 2023, <span style="-sec-ix-hidden:c307">four</span> of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 77% of the Company’s gross sales during the year and approximately 89% of its outstanding accounts receivable on December 31, 2023. For the year ended December 31, 2022, the same <span style="-sec-ix-hidden:c310">four</span> pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 72% of the Company’s gross sales during the year and 81% of its outstanding accounts receivable on December 31, 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Supplier Concentration </span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require long lead times. The Company has <span style="-sec-ix-hidden:c313"><span style="-sec-ix-hidden:c314">three</span></span> major raw material vendors that collectively accounted for approximately 83% and 80% of the raw material purchases by the Company in 2023 and 2022, respectively. In addition to the Company’s raw materials concentration, the Company utilizes one contract manufacturer for the production of its pharmaceutical product, Renacidin. Any disruption in this manufacturer’s operations could have a material impact on the Company’s revenue stream.</p>
CY2022 us-gaap Advertising Expense
AdvertisingExpense
19000 usd
CY2023Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
125000 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1031361 usd
CY2022Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
18590 usd
CY2023Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
6746727 usd
CY2022Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
497177 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8243122 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
830452 usd
CY2023 us-gaap Debt And Equity Securities Gain Loss
DebtAndEquitySecuritiesGainLoss
81095 usd
CY2022 us-gaap Debt And Equity Securities Gain Loss
DebtAndEquitySecuritiesGainLoss
-1046245 usd
CY2023 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
-433769 usd
CY2022 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
-364074 usd
CY2023 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
514864 usd
CY2022 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
-682171 usd
CY2023Q4 ug Certificates Of Deposit Cost
CertificatesOfDepositCost
275000 usd
CY2023Q4 ug Certificates Of Deposit Fair Value
CertificatesOfDepositFairValue
275000 usd
CY2023Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Cost
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost
849330 usd
CY2023Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Fair Value
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue
851318 usd
CY2023Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Unrealized Gain Loss
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss
1988 usd
CY2022Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
6166392 usd
CY2022Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
5653516 usd
CY2022Q4 ug Equity Securities Fvni Accumulated Unrealized Gain Loss
EquitySecuritiesFvniAccumulatedUnrealizedGainLoss
-512876 usd
CY2022Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Cost
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost
6166392 usd
CY2022Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Fair Value
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue
5653516 usd
CY2022Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Unrealized Gain Loss
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss
-512876 usd
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5505145 usd
CY2023 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
-433769 usd
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2867671 usd
CY2022 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
-364074 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
476501 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
601125 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
92089 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
16520 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
654916 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1054367 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1223506 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1672012 usd
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
47000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
64000 usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
609006 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
850344 usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
788 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1590 usd
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
609794 usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
851934 usd
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
59614 usd
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-193766 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
59614 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-193766 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
669408 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
658168 usd
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
682664 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
677813 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
623 usd
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1256 usd
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
14000 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.004 pure
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
10000 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.003 pure
CY2022 us-gaap Income Tax Reconciliation Deductions Dividends
IncomeTaxReconciliationDeductionsDividends
6300 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Deductions Dividends
EffectiveIncomeTaxRateReconciliationDeductionsDividends
0.002 pure
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-4601 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
669408 usd
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.206 pure
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
658168 usd
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.204 pure
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
3501 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
4213 usd
CY2023Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
9870 usd
CY2022Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
13440 usd
CY2023Q4 ug Deferred Tax Assets Accounts Payable
DeferredTaxAssetsAccountsPayable
28235 usd
CY2022Q4 ug Deferred Tax Assets Accounts Payable
DeferredTaxAssetsAccountsPayable
6367 usd
CY2023Q4 ug Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
159838 usd
CY2022Q4 ug Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
92756 usd
CY2022Q4 us-gaap Deferred Tax Assets Unrealized Losses On Availablefor Sale Securities Gross
DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross
107704 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
285200 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
277326 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
486644 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
501806 usd
CY2023Q4 ug Deferred Tax Liabilities Accounts Receivable
DeferredTaxLiabilitiesAccountsReceivable
332537 usd
CY2022Q4 ug Deferred Tax Liabilities Accounts Receivable
DeferredTaxLiabilitiesAccountsReceivable
304004 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
46484 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
42446 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
56275 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
44812 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Unrealized Gains On Trading Securities
DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
418 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
435714 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
391262 usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
50930 usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
110544 usd
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
83000 usd
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
81000 usd
CY2022 ug Defined Contribution Plan Employer Discretionary Contribution Amount Per Year Authorized
DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized
109000 usd
CY2023 ug Defined Contribution Plan Employer Discretionary Contribution Amount Per Year Authorized
DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized
109000 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
96157 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
53475 usd
CY2023 ug Revenue From Contract With Customer Including Assessed Tax Gross
RevenueFromContractWithCustomerIncludingAssessedTaxGross
11979517 usd
CY2022 ug Revenue From Contract With Customer Including Assessed Tax Gross
RevenueFromContractWithCustomerIncludingAssessedTaxGross
13905962 usd
CY2023 ug Sales Returns And Allowances
SalesReturnsAndAllowances
1094363 usd
CY2022 ug Sales Returns And Allowances
SalesReturnsAndAllowances
1207459 usd
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10885154 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12698503 usd
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10885154 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12698503 usd
CY2023 ug Revenue From Contract With Customer Including Assessed Tax Gross
RevenueFromContractWithCustomerIncludingAssessedTaxGross
11979517 usd
CY2022 ug Revenue From Contract With Customer Including Assessed Tax Gross
RevenueFromContractWithCustomerIncludingAssessedTaxGross
13905962 usd
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
187002 usd
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
175496 usd
CY2023Q4 ug Accrued Distribution Fees Current
AccruedDistributionFeesCurrent
407133 usd
CY2022Q4 ug Accrued Distribution Fees Current
AccruedDistributionFeesCurrent
395536 usd
CY2023Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
109000 usd
CY2022Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
94326 usd
CY2023Q4 ug Accrued Annual Report Expenses Current
AccruedAnnualReportExpensesCurrent
81725 usd
CY2022Q4 ug Accrued Annual Report Expenses Current
AccruedAnnualReportExpensesCurrent
68349 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
71000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
66500 usd
CY2023Q4 ug Accrued Reserve For Outdated Material
AccruedReserveForOutdatedMaterial
247847 usd
CY2022Q4 ug Accrued Reserve For Outdated Material
AccruedReserveForOutdatedMaterial
369154 usd
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
132250 usd
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
80926 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30930 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18294 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1363044 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1322056 usd
CY2023Q4 ug Convertible Common Stock Shares Issuable Upon Conversion
ConvertibleCommonStockSharesIssuableUponConversion
447
CY2023 ug Payments For Accrued Dividends On Unconverted Shares
PaymentsForAccruedDividendsOnUnconvertedShares
447 usd

Files In Submission

Name View Source Status
0001171843-24-001526-index-headers.html Edgar Link pending
0001171843-24-001526-index.html Edgar Link pending
0001171843-24-001526.txt Edgar Link pending
0001171843-24-001526-xbrl.zip Edgar Link pending
ex_640383.htm Edgar Link pending
ex_640384.htm Edgar Link pending
ex_640385.htm Edgar Link pending
ex_640386.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ug-20231231.xsd Edgar Link pending
ug20231231_10k.htm Edgar Link pending
ug-20231231_lab.xml Edgar Link unprocessable
ug-20231231_pre.xml Edgar Link unprocessable
ug20231231_10k_htm.xml Edgar Link completed
ug-20231231_def.xml Edgar Link unprocessable
ug-20231231_cal.xml Edgar Link unprocessable